Skip to content
DaveManuel.com · Institutional Ownership · 13F Holdings

Lynx1 Capital Management LP

Reported holdings as of Q2 2026, from 19 quarterly filings.

CIK
1910456
Reported value
$865.5M
Positions
27
Top 10 weight
98.8%
Filed
2026-08-13
Days after quarter end
44

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
GH RESEARCH PLCGHRS$356.5M13,263,28841.19%+17.27pp13q+23.2%+$67.2M
CULLINAN THERAPEUTICS INCCGEM$163.2M8,963,50018.86%-1.27pp9qHELD
STOKE THERAPEUTICS INCSTOK$132.1M4,038,40415.27%-9.25pp12q-15.2%-$23.7M
AGIOS PHARMACEUTICALS INCAGIO$126.5M3,408,93714.62%+0.65pp3q+30.5%+$29.6M
C4 THERAPEUTICS INCCCCC$34.2M7,326,6913.95%+1.04pp12q+4.7%+$1.5M
KORRO BIO INCKRRO$20.3M1,538,2962.34%-0.41pp3qHELD
TSCAN THERAPEUTICS INCTCRX$7.9M8,019,1480.91%-0.37pp13qHELD
PRECISION BIOSCIENCES INCDTIL$7.5M950,4660.86%+0.01pp7q-3.5%-$272.3K
NEUPHORIA THERAPEUTICS INCNEUP$3.8M875,3280.44%-0.12pp3qHELD
PASSAGE BIO INC COM NEWPASG$3.3M673,7590.38%-0.39pp4q+8.0%+$244.3K
CG ONCOLOGY INCCGON$2.2M31,3910.26%-0.08pp3q-0.6%-$14.2K
PLIANT THERAPEUTICS INCPLRX$2.0M1,798,0700.24%-newNEW
ENTRADA THERAPEUTICS INCTRDA$1.3M178,6060.15%-0.27pp3q-15.6%-$243.5K
VYNE THERAPEUTICS INCVYNE$1.1M1,628,7000.12%-0.03pp2qHELD
ProQR Therapeutics BV (NetherlPRQR$969.8K521,4130.11%+0.09pp3q+661.3%+$842.4K
TRAWS PHARMA INCTRAW$471.8K559,4700.05%+0.05pp2q+3610.5%+$459.1K
FOGHORN THERAPEUTICS INCFHTX$300.5K61,5880.03%-newNEW
DENALI THERAPEUTICS INCDNLI$299.8K11,6580.03%-5.67pp4q-99.4%-$48.1M
XENCOR INCXNCR$292.9K18,1940.03%-0.99pp3q-96.6%-$8.3M
ABSCI CORPORATIONABSI$246.2K21,2450.03%+0.02pp2qHELD
WEREWOLF THERAPEUTICS INCHOWL$236.7K657,7860.03%-0.06pp3qHELD
IMMATICS N.VIMTX$235.4K23,2360.03%-0.31pp3q-89.3%-$2.0M
AVALO THERAPEUTICS INCAVTX$186.6K10,1000.02%-newNEW
BOLT BIOTHERAPEUTICSBOLT$118.6K30,8000.01%-0.01pp2qHELD
NUVATION BIO INCNUVB$91.0K16,0290.01%-newNEW
Eupraxia Pharmaceuticals IncEPRX$66.1K10,0000.01%-newNEW
INHIBIKASE THERAPEUTICS INCIKT$40.6K20,0000.00%-newNEW

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 99.9%Not classified 0.1%
 
SectorValueShare
Biotech & Pharma$864.5M99.9%
Not classified$1.1M0.1%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q2 2026+33.9%+14.8%+19.1%100%
Q1 2026+12.8%-4.6%+17.4%100%
Q4 2025+11.0%+2.4%+8.7%107%
Q3 2025+46.6%+7.8%+38.8%99%
Q2 2025+17.0%+10.5%+6.6%100%
Q1 2025-18.2%-4.6%-13.6%100%
Q4 2024-17.5%+2.1%-19.6%100%
Q3 2024-12.2%+5.4%-17.7%100%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$865.5M27667298.8%44
Q1 2026$632.7M23565497.1%34
Q4 2025$494.0M221351597.2%48
Q3 2025$491.3M14334498.8%44
Q2 2025$346.2M15160098.8%45
Q1 2025$279.2M14252698.2%45
Q4 2024$266.7M18751795.8%45
Q3 2024$282.2M18463399.2%45
Q2 2024$277.2M17753698.9%45
Q1 2024$388.2M16276196.8%45
Q4 2023$254.3M15081397.1%45
Q3 2023$151.2M18716793.7%45
Q2 2023$152.6M18647196.1%45
Q1 2023$119.9M13174198.0%45
Q4 2022$115.6M13472398.0%45
Q3 2022$110.9M12064096.7%45
Q2 2022$117.4M12191399.1%46
Q1 2022$107.7M14463098.5%46
Q4 2021$114.6M100000100.0%45

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.